Locke Lord’s IP Pharmaceutical and Biotechnology practice pulls together attorneys from across the firm’s many practice areas and offices who are best suited to meet the legal challenges of pharmaceutical and biotechnology industry clients. Our formidable team combines strong scientific understanding, courtroom experience, regulatory expertise and industry knowledge. Our attorneys have been recognized in Chambers, Benchmark Litigation’s 2010 Definitive Guide to America’s Leading Litigation Firms and Attorneys, The Best Lawyers in America, and Super Lawyers and our accomplishments have been reported in The American Lawyer, The National Law Journal, and Legal Times. Some of the largest pharmaceutical, biotechnology, and agricultural companies in the world rely on Locke Lord.
Our lawyers have technical skills and expertise in a variety of scientific fields, including: pharmaceuticals; organic, inorganic and industrial chemistry; biochemistry; biotechnology; and genetics. Many of our lawyers and scientific advisors have Ph.D.s in the chemical and biological arts. Our real world experience enables us to counsel clients on virtually any legal issue surrounding a lawsuit or transaction without losing sight of the science or technology involved.
Pharmaceutical and biotechnology companies also turn to us for assistance in structuring transactions, building strategically solid portfolios and identifying and protecting IP rights. Our services include patenting groundbreaking advancements, helping clients navigate “patent thickets” surrounding new technologies, representing clients’ interests in U.S. Patent & Trademark Office proceedings (interference contests and reexamination proceedings, and appeals with the Board of Patent Appeals and Interferences), and providing opinions on patent non-infringement and invalidity. We also assist clients in devising strategies for acquiring, licensing and asserting intellectual property rights and in managing global patent portfolios to ensure the strongest patent protection through consistent prosecution in various jurisdictions.
Working with their clients, Locke Lord attorneys and scientific advisors have developed and executed successful intellectual property strategies for a range of technologies such as immunology, vaccines, neurobiology, growth factors, protein expression, PCR, pharmaceuticals (protein-based and small molecule), lipid-based drug delivery systems, gene therapy, phage display and microarrays. Locke Lord’s seasoned team has the experience and expertise to protect our client’s most valuable pharmaceutical and biotechnology IP assets.
Seed World Wrangling
The Evolving Standard for Declaratory Judgment Jurisdiction In Hatch-Waxman Act Litigation
Federal Circuit Turns Down Forest Bid, Won't Rehear Standing Issue in Lexapro Case
Locke Lord Elects Seven New Partners in Four U.S. Cities; Practice Areas Include IP Pharmaceutical, Litigation, Bankruptcy
Locke Lord Bissell & Liddell Elevates Eight Associates to Partner
Locke Lord Bissell & Liddell Attorneys Recognized Among The Best Lawyers in America 2010
Locke Lord Bissell & Liddell Signs Up More Than 30 Attorneys Previously With Prestigious New York-Based Morgan & Finnegan; Opening San Francisco Office
Locke Liddell & Sapp's IP Section Named Among Top 10 in the Country
|Disclaimer & Trademark Notice
© 2013 Locke Lord LLP